Comparative Pharmacology
Head-to-head clinical analysis: HYDELTRASOL versus STATROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDELTRASOL versus STATROL.
HYDELTRASOL vs STATROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory and immunosuppressive properties; suppresses multiple inflammatory cytokines and induces lipocortin synthesis.
Statrol is a combination antibiotic ointment containing polymyxin B sulfate, neomycin sulfate, and gramicidin. Polymyxin B binds to lipopolysaccharides in the outer membrane of gram-negative bacteria, disrupting membrane integrity. Neomycin inhibits protein synthesis by binding to the 30S ribosomal subunit. Gramicidin alters cell membrane permeability in gram-positive bacteria by forming ion channels.
Intravenous: Initial dose 100-250 mg, then repeat every 10-30 minutes as needed. Intramuscular: 100-250 mg every 10-30 minutes. Intra-articular: 10-40 mg per joint every 1-2 weeks.
10 mg orally once daily
None Documented
None Documented
Terminal half-life ~2-3 hours; clinically, adrenal suppression may persist >24h.
Terminal half-life 12-16 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renally eliminated: ~80% as metabolites, <10% unchanged. Biliary/fecal: minor.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites, 10% unchanged.
Category C
Category C
Corticosteroid
Otic Antibiotic/Corticosteroid